The major plasmin inhibitors namely alpha2-plasmin inhibitor and alpha2-macroglobulin were compared for their effects on lysis of fibrin clot. Plasmin fibrinolytic activity was immediately inhibited by alpha2-plasmin inhibitor, whereas alpha2-macroglobulin inhibited plasmin progressively. Urokinase(plasminogen activator)-induced clot lysis was inhibited efficiently by alpha2-plasmin inhibitor present in the clot. Inhibition of urokinase-induced clot lysis by alpha2-macroglobulin was weak and the molar concentration necessary for alpha2-macroglobulin to achieve the same degree of inhibition as that achieved with alpha2-plasmin inhibitor was about 10 times higher than that of alpha2-plasmin inhibitor. Binding of Lys-plasminogen to fibrin was inhibited by alpha2-plasmin inhibitor but not by alpha2-macroglobulin. Molar concentrations of alpha2-plasmin inhibitor which were effective in inhibiting the binding were 30 times less than that of 6-aminohexanoicacid. alpha2-Plasmin inhibitor was found to interact with Lys-plasminogen to form a weakly-bound complex which is dissociable in the presence of 6-aminohexanoic acid, suggesting that inhibition of binding of Lys-plasminogen to fibrin by alpha2-plasmin inhibitor may be due to interaction of alpha2-plasmin inhibitor with a specific site of the plasminogen molecule and that the site may be 6-aminohexanoic acid-binding site. It is suggested that alpha2-plasmin inhibitor is more reactive and efficient inhibitor of fibrinolysis than alpha 2-macroglobulin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Plasma tissue plasminogen activator-inhibitor complex levels in acute myocardial infarction patients: an observational study.
BMC Cardiovasc Disord
December 2024
Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China.
Introduction: The activation of the plasmatic coagulation system is a significant contributor to acute myocardial infarction (AMI). This study aimed to investigate the association between the levels of tissue plasminogen activator-inhibitor complex (t-PAIC), thrombin-antithrombin complex (TAT), plasmin-α2 plasmin-inhibitor complex (PIC), and thrombomodulin (TM) with clinical outcomes in patients with AMI.
Methods: Blood samples were collected from 368 patients presenting with acute myocardial infarction in the emergency department to assess levels of t-PAIC, TAT, PIC, and TM.
Localization of Hemostasis Elements in Aspirated Coronary Thrombi at Different Stages of Evolution.
Int J Mol Sci
November 2024
Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Article Synopsis
- The study investigates the structure and evolution of coronary thrombi in STEMI, focusing on the role of activated protein C (APC/PC) and factors like factor XIII (FXIII) and α2 plasmin inhibitor (α2-PI).
- Histopathological analysis of thrombi from 24 male patients revealed that thrombus age (fresh, lytic, organized) affects the levels and distribution of APC/PC, FXIII, and α2-PI.
- Key findings indicate that FXIII is highly co-localized with fibrin, while α2-PI increases during thrombus lysis, and NET markers are most prominent in the lytic phase, highlighting potential therapeutic strategies for STEMI.
Impact of different energy sources on coagulation biomarkers and silent cerebral events in balloon-based ablation for atrial fibrillation.
Heart Rhythm O2
August 2024
Department of Cardiology, Fujita Health University, Toyoake, Japan.
Background: Different energy sources of balloon-based ablation for pulmonary vein isolation cause different kinds of endothelial damage and coagulation responses associated with thromboembolic risk.
Objectives: The study sought to compare the impact of different balloon-based ablation, cryoballoon ablation (CBA) and laser balloon ablation (LBA), on coagulation/fibrinolysis biomarkers and silent cerebral events (SCEs) in paroxysmal atrial fibrillation.
Methods: Paroxysmal atrial fibrillation patients who underwent pulmonary vein isolation using either CBA (n = 52) or LBA (n = 53) without radiofrequency touch-up ablation were eligible.
Detection of factor XIII inhibitors in 33 patients with autoimmune factor XIII deficiency in Japan.
Int J Hematol
October 2024
Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, 990-9585, Japan.
Article Synopsis
- Autoimmune factor XIII (FXIII) deficiency (AiF13D) is a rare disease caused by anti-FXIII autoantibodies that disrupt FXIII function, classified into three types with different effects on FXIII activity.
- A new assay, called the PI-BAPA assay, has been developed to effectively detect types Aa and Ab FXIII inhibitors which can be lethal if missed by standard tests.
- This assay demonstrated high specificity and sensitivity in trials with 128 plasma samples, outperforming traditional methods, and is now being utilized for diagnosing AiF13D.
Predictive value of thrombin-antithrombin III complex and tissue plasminogen activator-inhibitor complex biomarkers in assessing the severity of early-stage acute pancreatitis.
J Gastroenterol Hepatol
October 2024
Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
Background And Aim: The development of acute pancreatitis (AP) is strongly linked to blood clotting and fibrinolysis issues. Modern clinical practices now utilize advanced blood markers like thrombin-antithrombin III complex (TAT), plasmin-α2-plasmin inhibitor complex, thrombomodulin (TM), and tissue plasminogen activator-inhibitor complex (t-PAIC) to assess thrombosis risk. Our study used a highly sensitive chemiluminescence technique to measure these markers in AP patients, aiming to determine their early predictive value for AP severity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!